Our purpose is to mitigate the global crisis of antibiotic failure by improving patients’ odds of survival and quality of life.
Together, our diagnostic and therapeutic solutions represent tremendous clinical and commercial potential, through rapid diagnosis and uniquely effective treatment.
Novel diagnostic assay for the early and rapid diagnosis of sepsis.
Dramatically faster diagnosis, for a health crisis where every hour counts.
Patented peptide technology targets infection-causing biofilms and reduces inflammation.
Effectively treats antibiotic-resistant infections, where nothing else works.
To continually innovate to address the global crisis of antibiotic failure, improving survivability and quality of life for patients.
To combine the best scientific, development and business teams to provide the best possible care to those suffering with antibiotic-resistant infections.
To become the global market leader in the diagnosis and treatment of antibiotic-resistant infections.
Rudy A. Mazzocchi
Chairman / CEO
Rudy A. Mazzocchi has over 30 years of senior executive management, technology and intellectual property development, and financing experience (institutional, venture, private and public) in the med-tech, biotech, and biopharma industries. As a founder of over a dozen healthcare companies, he has developed and commercialized multiple technologies ranging from diagnostics to implantable medical devices, requiring rigorous clinical validation and regulatory reviews, including FDA Clearance, CE Mark, and International Regulatory Approvals.
As Chairman/Acting-CEO of AGENTIX Biopharma Corp., he concurrently serves as Co-Founder/Vice-Chairman of the BioMedX Group, Executive Chairman of MY NEXT HEALTH and Independent Director of several private and public, early and growth-stage companies, and Senior Advisor to a variety of international corporations seeking global expansion and/or access to U.S. public markets. Mazzocchi previously served as Executive Chairman of Establishment Labs (NASDAQ:ESTA) and Independent Director of Greatbatch/Integer Medical (NYSE:ITGR).
Dr. Fadia Saad
Chief Business Development Officer
Dr. Saad has an extensive track record in strategic planning and implementation of significant projects for global companies. As Head of Business Development at Aspreva Pharmaceuticals, she produced licensing strategies and led teams in the analysis of licensing opportunities. She oversaw and directed all Business Development projects and assigned resources within established budget requirements, as well as managing operations of teams in R&D, intellectual property, finance and product commercialization.
Dr. Saad has led more than 15 on-site due diligences and played an integral role in negotiating a number of M&As of a cumulative value exceeding $2 Billion. She has a PhD in Microbiology from McGill University and an MBA from HEC (Hautes Etudes Commerciales), University of Montreal.
Dr. Robert Hancock
Chief Operations Officer / Director
Dr. Hancock is a leading microbiologist in Canada who has researched and taught at the University of British Columbia for nearly 40 years. His chief interest is in designing new therapeutic strategies to treat infections and inflammation in the light of increasing antibiotic resistance, coupled with a dearth of new antibiotic discovery. His research interests include cationic host defense peptides as novel antimicrobials, anti-biofilm agents, anti-inflammatory agents and modulators of innate immunity. He has published more than 760 papers and reviews, has more than 100,000 citations, an h-index of 162, and 65 patents awarded. Awards and honors include the Prix Galien (Highest award for Canadian Pharmaceutical Research and Innovation), the Killam Prize (Canada Council’s prize for Health Research), Michael Smith CIHR Researcher of the Year, and the ICAAC Aventis Antimicrobial Research Award (Leading award worldwide for antimicrobial research). In 2001 he was inducted as an Officer of the Order of Canada.
Chief Financial Officer
Jen Gretchen is an experienced finance and accounting professional. She obtained her CA designation in 2014 from the Canadian Institute of Chartered Accountants while articling with KPMG Vancouver in the technology and telecommunications sector. She has managerial experience in financial planning, analysis and reporting. She has spent her career working with progressive tech companies, including Qualcomm Incorporated and has assisted multiple companies through IPO and M&A transactions.
Dr. Evan Haney
Chief SCIENTIFIC Officer
Dr. Haney is an experienced scientist and research coordinator, who has managed a team of up to 20 individuals over the past 10 years. He is an inventor on the peptide patents that are core to ASEP’s therapeutic technology and has in-depth experience with the various endeavors relevant to clinical research. He has published over 40 papers in scientific journals related to peptide optimization and their development as therapeutics. Dr. Haney holds a Ph.D. in Biochemistry from the University of Calgary.
Board of Directors
Rudy A. Mazzocchi
CHAIRMAN / CEO
Dr. Robert Hancock
DIRECTOR / CHAIR – AUDIT COMMITTEE
Derrold Norgaard is a Fellow of the Chartered Professional Accountants of British Columbia. He held the dual role of Tax Partner and Office Managing Partner at KPMG until 2008. Norgaard’s primary areas of practice include personal tax planning, international tax and corporate taxation. He has authored several articles on Canadian tax planning and has been an instructor in Canadian tax programs for many years. He is a frequent speaker to business groups throughout Canada and Asia.
Tim Murphy is an experienced business executive and international lawyer. He is the Founding Partner of Murphy & Company, LLP, a leading business law firm in Vancouver, Canada, and has over 15 years of experience advising high growth companies on mergers and acquisitions, technology and finance matters. Mr. Murphy has executive experience as a CEO and has served on the boards of numerous public and private companies.